Rheumatic Immune-Related Adverse Events: Not Just Another IrAE

Save

Rheumatic immune-related adverse events can start at almost any time after the commencement after immune checkpoint inhibitor immunotherapy for cancer, and are liable to persist long after the immunotherapy has ceased, according to data presented at ACR 2019 in Atlanta, Georgia.

Herpes Zoster Vaccine Update

Save

Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older.

RheumNow Podcast –Favorites of ACR 2019 (11.22.19)

Save

Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.

A Focus on WOCBA (Women of Childbearing Age)

Save

Largely because it can be difficult to do studies in pregnant women, gaps remain in the area of rheumatic disease in pregnancy. This year’s ACR highlights some important new points to consider.

ACR 2019 - Report From Day 3 (Tuesday)

Save

Here's my summary of key studies presented Tuesday. 

Tofacitinib in Polyarticular JIA

ACR 2019 – Best of the Plenary Sessions

Save

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

ACR 2019 - Report from Day One (Sunday)

Save

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis

Autoinflammatory Diseases at the ACR Annual Meeting

Save

It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Save

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing.

RheumNow Podcast – ACR 2019 Round Up (11.15.19)

Save

Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.

RheumNow Podcast – Better Ways to Treat Gout (11.8.19)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Fight or Switching (DMARDs) (10.18.19)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

Save

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Save

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

Save

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Hydroxychloroquine Blood Levels May Predict Future Retinopathy

Save

A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.

ACR 2018 - Day 1 Report

Save

Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.

RheumNow Podcast – When You’re Hot You’re Hot (10.11.19)

Save

Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Save

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.